---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076809"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-06-23T20:02:33+00:00"
generated_at: "2026-06-23T20:04:23.292573+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem's VS-7375 shows 93% CA19-9 reduction in PDAC; plans Phase 3 in 1H2027

## Summary
- 93% (13/14) of heavily pretreated mPDAC patients at 900mg QD achieved >50% reduction in CA19-9; all remain on treatment.
- VS-7375 900mg QD achieved target plasma levels with clear PK separation from 600mg; safety profile favorable with low-grade GI AEs attenuating after cycle 1.
- Dose-dependent anti-tumor activity across PDAC, mCRC, and NSCLC; combination with cetuximab or Gem/NabP shows combinability without overlapping toxicities.
- Intends to collaborate with Erasca (ERAS) to evaluate VS-7375 + ERAS-0015 in preclinical models; future clinical trial collaboration possible.
- Key milestones: complete Phase 1/2 enrollment by June 2026; first patient in Phase 2 registration trials mid-2026; FDA meeting by end of 2026; Phase 3 start 1H2027.

## SEC filing metadata
- accession: 0001104659-26-076809
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-06-23T20:02:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/0001104659-26-076809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076809
- JSON: https://secwatch.observer/filing/0001104659-26-076809.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.